1,968
Views
4
CrossRef citations to date
0
Altmetric
Clinical Study

Association between vitamin D levels and mortality in hemodialysis patients: a cohort study

, , , , &
Pages 225-233 | Received 17 Jul 2019, Accepted 17 Feb 2020, Published online: 03 Mar 2020

References

  • Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11:e0158765.
  • Schiller A, Gadalean F, Schiller O, et al. Vitamin D deficiency – prognostic marker or mortality risk factor in end stage renal disease patients with diabetes mellitus treated with hemodialysis – a prospective multicenter study. PLoS One. 2015;10:e0126586.
  • Parikh C, Gutgarts V, Eisenberg E, et al. Vitamin D and clinical outcomes in dialysis. Semin Dial. 2015;28:604–609.
  • Soohoo M, Feng M, Obi Y, et al. Changes in markers of mineral and bone disorders and mortality in incident hemodialysis patients. Am J Nephrol. 2016;43:85–96.
  • Obi Y, Hamano T, Isaka Y. Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis Markers. 2015;2015:1–9.
  • Johnson RJ, Feehally J, Floege J. Comprehensive Clinical Nephrology. 5th ed. Philadelphia (PA): Elsevier; 2015.
  • Maeda SS, Borba VZ, Camargo MB, et al. Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D. Arq Bras Endocrinol Metab. 2014;58:411–433.
  • Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18:153–165.
  • Zheng Z, Shi H, Jia J, et al. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol. 2013;14:199.
  • Walker JP, Hiramoto JS, Gasper WJ, et al. Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease. J Vasc Surg. 2014;60:176–183.
  • Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. CJASN. 2012;7:358–365.
  • Pilz S, Iodice S, Zittermann A, et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58:374–382.
  • Kramer H, Berns JS, Choi MJ, et al. 25-Hydroxyvitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report. Am J Kidney Dis. 2014;64:499–509.
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76:S1–S130.
  • Vandenbroucke JP, von Elm E, Altman DG, et al; for the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297–1654.
  • Liu WC, Wu CC, Hung YM, et al. Pleiotropic effects of vitamin D in chronic kidney disease. Clin Chim Acta. 2016;453:1–12.
  • Delanaye P, Weekers L, Warling X, et al. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant. 2013;28:1779–1786.
  • Damasiewicz MJ, Toussaint ND. Is nutritional vitamin D supplementation beneficial in dialysis patients? Clin J Am Soc Nephrol. 2015;10:544–546.
  • Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017;9:328.
  • Bucharles S, Barberato SH, Stinghen AE, et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr. 2012;22:284–291.
  • Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5:905–911.
  • Carvalho JTG, Schneider M, Cuppari L, et al. Cholecalciferol decreases inflammation and improves vitamin D regulatory enzymes in lymphocytes in the uremic environment: a randomized controlled pilot trial. PloS One. 2017;12:e0179540.
  • Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013.
  • Mann MC, Hobbs AJ, Hemmelgarn BR, et al. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J. 2015;8:41–48.
  • Wang F, Wu S, Ruan Y, et al. Correlation of serum 25-hydroxyvitamin D level with vascular calcification in hemodialysis patients. Int J Clin Exp Med. 2015;8:15745–15751.
  • Wu S, Wang J, Wang F, et al. Oral active vitamin D treatment and mortality in maintenance hemodialysis patients. Cardiorenal Med. 2014;4:217–224.
  • Duranton F, Rodriguez-Ortiz ME, Duny Y, et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol. 2013;37:239–248.
  • St Peter WL, Weinhandl ED, Liu J. Vitamin D use and mortality in chronic kidney disease: immortal time bias. Arch Intern Med. 2008;168:2384–2386.
  • Brazilian Society of Nephrology. Dialysis Census 2016. [cited 2017 Jan 1]. Available from: http://www.censo-sbn.org.br/censosanteriores.